Bladder Instillations

Phase 2Small molecule

CCorewell Health East

Bladder Instillations is one of 2 small molecule programs targeting Cystitis, Interstitial. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystitis, InterstitialActive, not recruiting

Cystitis, InterstitialPhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Cystitis, Interstitial

#DrugCompanyPhaseTrials

Restasis

TTaiwan Bio Therapeutics Inc.

Phase 1

1 2

Bladder Instillations

CCorewell Health East

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Cystitis, Interstitial

NCT02870738

Clinical

Trials by Indication[1]

Cystitis, Interstitial1 trial

Comparison of Bladder Directed and Pelvic Floor Therapy in Women With Interstitial Cystitis/Bladder Pain Syndrome

Active, not recruiting·CCorewell Health East·Phase 2·NCT02870738·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bladder Instillations. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bladder Instillations compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bladder Instillations. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Corewell Health East company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCorewell Health East

Bladder Instillations

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Cystitis, Interstitial1 trial

References

Drug Info

Quick Facts

Related News